Today before the opening bell, International Stem Cell Corp.
announced that it has entered into the second phase of the existing Research
Agreement with Rohto Pharmaceutical Co., Ltd. (“Rohto”), a global Japanese
pharmaceutical company recognized as the second-largest consumer health company
in Japan.
Rohto acknowledged that ISCO’s human parthenogenetic neural
stem cells (hpNSCs) demonstrate consistent high quality and are suitable for
further use in Rohto’s research. This was determined after successfully
completing preliminary studies of ISCO’s proprietary cells. If Rohto
successfully validates hpNSCs’ efficacy in rodent models, which could lead to a
possible treatment of a variety of degenerative eye disorders, Rohto plans to
enter into negotiations of a definitive license agreement with ISCO in order to
license the company’s proprietary technology for therapeutic and commercial
use.
“Based on hpNSCs known performance in various animal models
we expect that in the next four months Rohto will be able to demonstrate the
efficacy of these stem cells in treating retinal degenerative disorders,”
stated Ruslan Semechkin, Ph.D., Chief Scientific Officer of ISCO.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
